• See Also
  1. Analgesic
  • Indications
  1. Moderate to severe acute pain in adults
  • Contraindications
  1. Severe hepatic Impairment (Child-Pugh Class C)
    1. Reduce dose in moderate hepatic Impairment
  • Mechanism
  1. Non-Opioid Analgesic with unique mechanism, released in 2024 at $15/pill
  2. Sodium Channel Blocker developed for use in acute pain
    1. Blocks transmission of Peripheral Nerve pain sesnsation
  • Dosing
  1. First Dose: 100 mg orally on an empty Stomach (except clear liquids)
    1. May be taken with clear liquids (water, apple juice, tea or black coffee)
    2. First dose should be taken >1 hour before or >2 hours after food
  2. Subsequent Doses: 50 mg orally every 12 hours
    1. May be taken with or without food
    2. May be used for up to 14 days (longer courses have not been studied)
  • Adverse Effects
  1. Pruritus
  2. Rash
  3. Myalgias
    1. May be associated with increased Creatine Phosphokinase (CPK)
  • Safety
  1. Avoid in pregnancy (unknown safety)
  2. Avoid in Lactation (present in animal milk, unknown safety)
  • Drug Interactions
  1. CYP3A Inhibitors
    1. Avoid with use of strong CYP3A Inhibitors (e.g. Itraconazole)
    2. Avoid Grapefruit juice while on Suzetrigine
  2. CYP3A Inducers
    1. Avoid with moderate to strong CYP3A Inducers (e.g. Rifampin)
  3. Progestins (other than Levonorgestrel or Norethindrone)
    1. If used for Contraception, use an alternate contracepive while taking Suzetrigine and for 28 days after
  • Efficacy
  1. Initial studies were with <1000 middle aged white women post-op (e.g. Bunion surgery, Abdominoplasty)
  2. Limited broader efficacy data
  3. Very expensive ($15/dose in 2025) for a medication with efficacy likely similar to Vicodin
  • Resources
  1. Suzetrigine (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f0976da4-1d20-4517-945c-b60ed2f41c12
  • References
  1. (2025) Presc Insights, Issue 3/2025